These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

• J9356

  Injection, trastuzumab, 10 mg and hyaluronidase-oysk

• J9357

  Injection, valrubicin, intravesical, 200 mg

• J9358

  Injection, fam-trastuzumab deruxtecan-nxki, 1 mg

• J9359

  Injection, loncastuximab tesirine-lpyl, 0.075 mg

• J9360

  Injection, vinblastine sulfate, 1 mg

• J9361

  Injection, efbemalenograstim alfa-vuxw, 0.5 mg

• J9370

  Vincristine sulfate, 1 mg

• J9371

  Injection, vincristine sulfate liposome, 1 mg

• J9376

  Injection, pozelimab-bbfg, 1 mg

• J9380

  Injection, teclistamab-cqyv, 0.5 mg

• J9381

  Injection, teplizumab-mzwv, 5 mcg

• J9382

  Injection, zenocutuzumab-zbco, 1 mg

• J9390

  Injection, vinorelbine tartrate, 10 mg

• J9393

  Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg

• J9394

  Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg

• J9395

  Injection, fulvestrant, 25 mg

• J9400

  Injection, ziv-aflibercept, 1 mg

• J9600

  Injection, porfimer sodium, 75 mg

• J9601

  Injection, linvoseltamab-gcpt, 1 mg

• J9999

  Not otherwise classified, antineoplastic drugs

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/4/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.